查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1534934

旅行疫苗市場:現狀分析與預測(2024年～2032年)

Travel Vaccine Market: Current Analysis and Forecast (2024-2032)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

旅行疫苗市場預計將呈現約9.5%的成長率。這主要是由於外科手術尤其是骨科手術的增加，增加了對DVT預防和治療的需求。疫苗開發和輸送系統的創新也提高了旅遊疫苗的有效性和可近性。預計這將進一步推動市場成長。例如，2021 年12 月，Emergent BioSolutions Inc. 宣布其第一階段試驗EBS-UFV-001 的第一項參與者研究已宣布，該研究旨在研究其在研通用流感疫苗候選藥物的安全性、耐受性和免疫原性。這最新版本的候選流感疫苗含有多種成分，旨在誘導針對甲型流感病毒的廣泛的、跨季節的免疫力。

市場依疾病類型分為肝炎、傷寒、流感、百白破、黃熱病等。由於甲型肝炎和乙型肝炎的風險不斷增加，尤其是在新興市場，肝炎類別預計將佔據旅行疫苗市場的最大市場佔有率。旅客尋求這些疫苗是因為這些衛生當局和國家的建議，以及在某些情況下的要求。這些宣傳活動、公司旅行政策以及國際旅行的出現也促進了這一增長。此外，肝炎疫苗的可用性、安全性和有效性也刺激了旅客對肝炎疫苗的高需求。另一方面，疫苗是旅行衛生的重要組成部分，因為參與政府旅行衛生評估有助於制定旅行衛生措施。

依旅行者類型，市場分為國內和國際。其中，國內類別預計將佔據旅行疫苗市場的最大市場佔有率，因為人們越來越多地前往本國不同地區，從而帶來不同的感染疾病風險。國內旅客從一個地區到另一個地區，或從城市到農村地區，或到疾病流行地區，因此可能會在所到地區接觸蜱傳腦炎或傷寒等疾病的疫苗接種。由於大流行後健康問題加劇，以及政府鼓勵當地旅遊業的活動，人們可能會在自己的國家/地區進行國內旅行並接種疫苗以確保安全旅行。這一趨勢對旅行疫苗的整體需求產生了積極影響，並正在推動全球市場的成長。

依年齡組，市場分為兒科、成人和老年。其中，成人品類細分市場也顯著提振了旅遊疫苗市場。成年人，尤其是 18 歲至 60 歲之間的成年人，佔休閒和商務旅行人口的大多數。該群體更有可能出國旅行，包括前往需要接種黃熱病、甲型肝炎、乙型肝炎和傷寒疫苗的高風險地區。成年人也更有可能遵循疫苗接種建議，因為他們通常對自己的健康決定負責。成人獨自旅行和探險旅行的趨勢進一步強化了全面疫苗接種的需求並推動市場成長。

為了更了解旅行疫苗的市場介紹，市場包括北美（美國、加拿大、歐洲其他地區）、歐洲（德國、英國、法國、西班牙、義大利、歐洲其他地區）、亞太地區（中國、根據世界其他地區（日本、印度、亞太其他地區）和世界其他地區的全球影響力進行分析。由於國際旅行頻繁、衛生法規嚴格以及人們對旅行相關健康風險的認識不斷增強，北美旅行疫苗市場的特點是需求強勁。該地區的市場得到了完善的醫療基礎設施、廣泛的疫苗覆蓋率以及疾病預防控制中心等衛生當局建議的積極疫苗接種政策的支持。這家北美公司提供全面的疫苗組合，利用先進的醫療技術進行分發，並專注於旅行者教育以確保廣泛接種疫苗。出境旅遊和商務旅行的增加進一步推動了該市場的成長，凸顯了該地區在全球旅行衛生措施中的關鍵作用。

市場上的主要公司包括默克（Merck & Co., Inc.）、輝瑞公司（Pfizer Inc.）、雅培製藥有限公司（Serum Institute of India Pvt. Ltd.）、阿斯特捷利康製藥公司（AstraZeneca） 。

目錄

第1章 市場簡介

  • 市場定義
  • 主要目的
  • 相關利益者
  • 限制事項

第2章 調查手法或前提條件

  • 調查流程
  • 調查手法
  • 受訪者簡介

第3章 摘要整理

  • 產業摘要
  • 各市場區隔預測
    • 市場成長的強度
  • 地區展望

第4章 市場動態

  • 促進因素
  • 機會
  • 阻礙因素
  • 趨勢
  • PESTEL分析
  • 需求面分析
  • 供給面分析
    • 合併和收購
    • 投資情勢
    • 產業洞察：主要新創公司及其獨特策略

第5章 價格分析

  • 各地區價格分析
  • 價格的影響因素

第6章 全球旅行疫苗市場收益，2022-2032年

第7章 各疾病類型的市場分析

  • 肝炎
  • 傷寒症
  • 流感
  • DPT
  • 黃熱病
  • 其他

第8章 各旅客類型的市場分析

  • 國內
  • 國際

第9章 各年齡層的市場分析

  • 兒童
  • 成人
  • 老年人

第10章 各地區的市場分析

  • 北美
    • 美國
    • 加拿大
    • 其他北美地區
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 全球其他地區

第11章 價值鏈分析

  • 限制分析
  • 市場參與企業一覽

第12章 競爭情形

  • 競爭儀表板
  • 競爭市場定位分析
  • 波特的五力分析

第13章 企業簡介

  • Merck & Co., Inc.
  • Sanofi
  • Novartis AG
  • Pfizer Inc.
  • EMERGENT
  • Abbott
  • Serum Institute of India Pvt. Ltd.
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca
  • GSK plc.

第14章 縮寫與前提條件

第15章 附錄

簡介目錄
Product Code: UMHE212933

The global travel vaccine ongoing and forthcoming encompasses vaccines manufactured for protecting travelers against diseases that are usually identifiable in diverse countries and are thus likely to affect travelers, these vaccines include Hepatitis A and B, typhoid, yellow fever, and rabies. Some of the forces that are currently fueling this market are the global traffic upsurge, improved consciousness of health risks associated with traveling, and official health guidelines and requirements from various governments and health institutions. Also, new technologies, new disease threats, and developments in travel-related infrastructures added to the market growth, so, traveling vaccinations are a key part of travel requirements.

The market for travel vaccine market is set to exhibit a growth rate of about 9.5%. This is mainly due to the rise in surgical procedures, especially orthopedic surgeries, which increases the need for DVT prophylaxis and treatment. Also, innovations in vaccine development and delivery systems enhance the efficacy and accessibility of travel vaccines. This will further boost market growth. For instance, In December 2021, Emergent BioSolutions Inc. declared the first participant dosed in its phase 1 study, EBS-UFV-001, studying the safety, tolerability, and immunogenicity of its investigational universal influenza vaccine candidate. The current and updated version of this influenza vaccine candidate includes multiple components intended to induce broad and supra-seasonal immunity against influenza A viruses.

Based on the disease type, the market is segmented into hepatitis, typhoid, influenza, DPT, yellow fever, and others. The hepatitis category is expected to have the largest market share of the travel vaccine market due to the increased risks of Hepatitis A and B in most tourism; especially those in the developing world. The traveling public seeks these vaccines because of the recommendations and in some cases, requirements of such health organizations and countries. These are awareness campaigns, corporate travel policies, and the emergence of international travel also catalyzed this growth. Further, accessibility of Hepatitis vaccines, safety, and efficacy also add to the high demand for Hepatitis vaccines midst travelers while government participation in touting travel health assessments contributes towards the formulation of travel health measures hence the vaccines in question form a significant cog in travel health.

Based on the tourist type, the market is segmented into domestic and international. Among these, the domestic category is expected to have the largest market share of the travel vaccine market due to the rising number of times that people visit different areas in their own countries, which puts them at different risks of getting diseases. Domestic tourists move from one region to another or from urban areas to rural areas or areas where the diseases are endemic and therefore, they require vaccinations of the diseases that are prevalent in the region they are visiting such as tick-borne encephalitis or typhoid fever. Due to government campaigns espousing local tourism as well as the post-pandemic increased concerns for health, people travel domestically within their countries and are likely to get vaccinated to ensure safe travels. This trend has a positive impact on the overall demand for travel vaccines and thus fuels the growth of the global market.

Based on the age group, the market is segmented into pediatrics, adults, and geriatrics. Among these, the adult category segment also significantly boosts the travel vaccine market. Adults, especially those between 18 and 60, constitute a major portion of the traveling population for both leisure and business purposes. This demographic is more likely to travel to international destinations, including regions with higher health risks, necessitating vaccinations for diseases like yellow fever, Hepatitis A and B, and typhoid. Additionally, as adults are typically responsible for their health decisions, they are more likely to adhere to vaccination recommendations. The increasing trend of solo travel and adventure tourism among adults further elevates the need for comprehensive vaccination, driving market growth.

For a better understanding of the market adoption of travel vaccines, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The North American travel vaccine market is characterized by robust demand driven by a high volume of international travel, stringent health regulations, and increasing awareness of travel-related health risks. The region's market is bolstered by established healthcare infrastructure, widespread availability of vaccines, and proactive vaccination policies recommended by health authorities such as the CDC. Companies in North America focus on offering comprehensive vaccine portfolios, leveraging advanced healthcare technologies for distribution, and emphasizing traveler education to ensure widespread adoption of vaccinations. The market's growth is further propelled by rising outbound tourism and business travel, highlighting the region's pivotal role in global travel health initiatives.

Some of the major players operating in the market include Merck & Co., Inc.; Sanofi; Novartis AG; Pfizer Inc.; EMERGENT; Abbott; Serum Institute of India Pvt. Ltd.; Takeda Pharmaceutical Company Limited; AstraZeneca; and GSK plc.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Global Travel Vaccine Market
  • 2.2. Research Methodology of the Global Travel Vaccine Market
  • 2.3. Respondent Profile

3.EXECUTIVE SUMMARY

  • 3.1. Industry Synopsis
  • 3.2. Segmental Outlook
    • 3.2.1. Market Growth Intensity
  • 3.3. Regional Outlook

4.MARKET DYNAMICS

  • 4.1. Drivers
  • 4.2. Opportunity
  • 4.3. Restraints
  • 4.4. Trends
  • 4.5. PESTEL Analysis
  • 4.6. Demand Side Analysis
  • 4.7. Supply Side Analysis
    • 4.7.1. Merger & Acquisition
    • 4.7.2. Investment Scenario
    • 4.7.3. Industry Insights: Leading Startups and Their Unique Strategies

5.PRICING ANALYSIS

  • 5.1. Regional Pricing Analysis
  • 5.2. Price Influencing Factors

6.GLOBAL TRAVEL VACCINE MARKET REVENUE (USD BN), 2022-2032F

7.MARKET INSIGHTS BY DISEASE TYPE

  • 7.1. Hepatitis
  • 7.2. Typhoid
  • 7.3. Influenza
  • 7.4. DPT
  • 7.5. Yellow Fever
  • 7.6. Others

8.MARKET INSIGHTS BY TOURIST TYPE

  • 8.1. Domestic
  • 8.2. International

9.MARKET INSIGHTS BY AGE GROUP

  • 9.1. Pediatrics
  • 9.2. Adults
  • 9.3. Geriatrics

10.MARKET INSIGHTS BY REGION

  • 10.1. North America
    • 10.1.1. U.S.
    • 10.1.2. Canada
    • 10.1.3. Rest of North America
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. U.K.
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Rest of Asia-Pacific
  • 10.4. Rest of World

11.VALUE CHAIN ANALYSIS

  • 11.1. Marginal Analysis
  • 11.2. List of Market Participants

12.COMPETITIVE LANDSCAPE

  • 12.1. Competition Dashboard
  • 12.2. Competitor Market Positioning Analysis
  • 12.3. Porter Five Forces Analysis

13.COMPANY PROFILED

  • 13.1. Merck & Co., Inc.
    • 13.1.1. Company Overview
    • 13.1.2. Key Financials
    • 13.1.3. SWOT Analysis
    • 13.1.4. Product Portfolio
    • 13.1.5. Recent Developments
  • 13.2. Sanofi
  • 13.3. Novartis AG
  • 13.4. Pfizer Inc.
  • 13.5. EMERGENT
  • 13.6. Abbott
  • 13.7. Serum Institute of India Pvt. Ltd.
  • 13.8. Takeda Pharmaceutical Company Limited
  • 13.9. AstraZeneca
  • 13.10. GSK plc.

14.ACRONYMS & ASSUMPTION

15.ANNEXURE